A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

Sponsor:

Bristol Myers Squibb

Sponsor Study ID:

CA071-1000

CTO #:

104150

NCT Number:

NCT06764485

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Prostate

Study Objectives:

To compare the efficacy of BMS-986365 vs investigator s choice of therapy. To compare the efficacy of BMS-986365 vs investigator s choice of therapy. Part 1 only: to inform the dose of BMS-986365 to continue in part 2 of the study. To further assess the efficacy of BMS-986365 vs investigator s choice of therapy. To investigate the effect on PROs in this study population when treated with BMS-986365 vs investigator's choice of therapy.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)